Novartis CEO: What's passé, and what to watch

Novartis is restructuring, with aims to focus more intently on “specialized and more personalized innovative medicines,” per CEO Vas Narasimhan, who spoke with STAT on his new game plan. Contact lenses have been culled from the business, whereas cancer immunotherapy will increasingly get more backing. Gene therapy is “really at a pivotal point,” and digital therapeutics are picking up steam in Narasimhan’s eyes.

“My ultimate dream would be to find signatures of high-responding patients through … artificial intelligence, and prospectively identify: Who will be the super-responders?” he told STAT.